Linking cardiometabolic disorders to sporadic Alzheimer's disease: A perspective on potential mechanisms and mediators (pages 551-562)

Journal of Neurochemistry

Volumn 115, Issue 3, 2010, Pages 551-562

  Bhat, Narayan R ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Alzheimer's disease; Cholesterol; Diabetes; Inflammation; Insulin resistance; Metabolic syndrome

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIVER X RECEPTOR AGONIST; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; SOMATOMEDIN C;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; BLOOD BRAIN BARRIER; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; DIABETES MELLITUS; DIETARY INTAKE; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; INCIDENCE; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE; METABOLIC SYNDROME X; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; CEREBROVASCULAR DISORDERS; DIABETES COMPLICATIONS; DIET; HEART DISEASES; HUMANS; INSULIN RESISTANCE; LIFE STYLE; METABOLIC DISEASES; METABOLIC SYNDROME X; RISK;

ANIMALIA;

EID: 78651294089     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06978.x     Document Type: Review

References (126)

1. Akiyama H., Barger S., Barnum S. et al. (2000) Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421.
2. Aleman A. and Torres-Aleman I. (2009) Circulating insulin-like growth factor I and cognitive function: Neuromodulation throughout the lifespan. Prog. Neurobiol. 89, 256-265.
3. Audoy-Remus J., Richard J. F., Soulet D., Zhou H., Kubes P. and Vallieres L. (2008) Rod-Shaped monocytes patrol the brain vasculature and give rise to perivascular macrophages under the influence of proinflammatory cytokines and angiopoietin-2. J. Neurosci. 28, 10187-10199.
4. Auffray C., Sieweke M. H. and Geissmann F. (2009) Blood monocytes: Development, heterogeneity, and relationship with dendritic cells. Annu. Rev. Immunol. 27, 669-692.
5. Balaraman Y., Limaye A. R., Levey A. I. and Srinivasan S. (2006) Glycogen synthase kinase 3beta and Alzheimer's disease: Pathophysiological and therapeutic significance. Cell. Mol. Life Sci. 63, 1226-1235.
6. Banks W. A. and Erickson M. A. (2010) The blood-brain barrier and immune function and dysfunction. Neurobiol. Dis. 37, 26-32.
7. Bell R. D. and Zlokovic B. V. (2009) Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol. 118, 103-113.
8. Biessels G. J., Kamal A., Urban I. J., Spruijt B. M., Erkelens D. W. and Gispen W. H. (1998) Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: Effects of insulin treatment. Brain Res. 800, 125-135.
9. Bjorkhem I. (2006) Crossing the barrier: Oxysterols as cholesterol transporters and metabolic modulators in the brain. J. Intern. Med. 260, 493-508.
10. Boura-Halfon S. and Zick Y. (2009) Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 296, E581-E591.
11. Bourlier V. and Bouloumie A. (2009) Role of macrophage tissue infiltration in obesity and insulin resistance. Diabetes Metab. 35, 251-260.
12. Braak H., Braak E. and Bohl J. (1993) Staging of Alzheimer-related cortical destruction. Eur. Neurol. 33, 403-408.
13. Bruce K. D. and Byrne C. D. (2009) The metabolic syndrome: Common origins of a multifactorial disorder. Postgrad. Med. J. 85, 614-621.
14. Buga G. M., Frank J. S., Mottino G. A. et al. (2006) D-4F decreases brain arteriole inflammation and improves cognitive performance in LDL receptor-null mice on a Western diet. J. Lipid Res. 47, 2148-2160.
15. Cao D., Lu H., Lewis T. L. and Li L. (2007) Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J. Biol. Chem. 282, 36275-36282.
16. Casserly I. and Topol E. (2004) Convergence of atherosclerosis and Alzheimer's disease: Inflammation, cholesterol, and misfolded proteins. Lancet 363, 1139-1146.
17. Cechetto D. F., Hachinski V. and Whitehead S. N. (2008) Vascular risk factors and Alzheimer's disease. Expert Rev. Neurother. 8, 743-750.
18. Chen Y., Zhou K., Wang R. et al. (2009) Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc. Natl Acad. Sci. USA 106, 3907-3912.
19. Cohen E. and Dillin A. (2008) The insulin paradox: Aging, proteotoxicity and neurodegeneration. Nat. Rev. Neurosci. 9, 759-767.
20. Cohen E., Paulsson J. F., Blinder P. et al. (2009) Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell 139, 1157-1169.
21. Cole G. M. and Frautschy S. A. (2007) The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's disease. Exp. Gerontol. 42, 10-21.
22. Cole G. M. and Frautschy S. A. (2010) DHA may prevent age-related dementia. J. Nutr. 140, 869-874.
23. Colton C. A. (2009) Heterogeneity of microglial activation in the innate immune response in the brain. J. Neuroimmune Pharmacol. 4, 399-418.
24. Craft S. (2009) The role of metabolic disorders in Alzheimer disease and vascular dementia: Two roads converged. Arch. Neurol. 66, 300-305.
25. De Felice F. G., Vieira M. N., Bomfim T. R., Decker H., Velasco P. T., Lambert M. P., Viola K. L., Zhao W. Q., Ferreira S. T. and Klein W. L. (2009) Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc. Natl Acad. Sci. USA 106, 1971-1976.
26. Dhamoon M. S., Noble J. M. and Craft S. (2009) Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 72, 292-293.
27. D'Mello C., Le T. and Swain M. G. (2009) Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. J. Neurosci. 29, 2089-2102.
28. Eikelenboom P., Veerhuis R., Familian A., Hoozemans J. J., van GoolW. A. and Rozemuller A. J. (2008) Neuroinflammation in plaque and vascular beta-amyloid disorders: Clinical and therapeutic implications. Neurodegener. Dis. 5, 190-193.
29. Engel T., Hernandez F., Avila J. and Lucas J. J. (2006) Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J. Neurosci. 26, 5083-5090.
30. van Es M. A. and van den Berg L. H. (2009) Alzheimer's disease beyond APOE. Nat. Genet. 41, 1047-1048.
31. Fitz N. F., Cronican A., Pham T., Fogg A., Fauq A. H., Chapman R., Lefterov I. and Koldamova R. (2010) Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice. J. Neurosci. 30, 6862-6872.
32. Fonseca A. C., Resende R., Oliveira C. R. and Pereira C. M. (2010) Cholesterol and statins in Alzheimer's disease: Current controversies. Exp. Neurol. 223, 282-293.
33. Franciosi S., Gama Sosa M. A., English D. F. et al. (2009) Novel cerebrovascular pathology in mice fed a high cholesterol diet. Mol. Neurodegener. 4, 42.
34. Freude S., Schilbach K. and Schubert M. (2009) The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: From model organisms to human disease. Curr. Alzheimer Res. 6, 213-223.
35. Gate D., Rezai-Zadeh K., Jodry D., Rentsendorj A. and Town T. (2010) Macrophages in Alzheimer's disease: The blood-borne identity. J. Neural Transm. 117, 961-970.
36. Getts D. R., Terry R. L., Getts M. T., Muller M., Rana S., Shrestha B., Radford J., Van Rooijen N., Campbell I. L. and King N. J. (2008) Ly6c+ "inflammatory monocytes" are microglial precursors recruited in a pathogenic manner in West Nile virus encephalitis. J. Exp. Med. 205, 2319-2337.
37. Grammas P., Samany P. G. and Thirumangalakudi L. (2006) Thrombin and inflammatory proteins are elevated in Alzheimer's disease microvessels: Implications for disease pathogenesis. J. Alzheimers Dis. 9, 51-58.
38. Granholm A. C., Bimonte-Nelson H. A., Moore A. B., Nelson M. E., Freeman L. R. and Sambamurti K. (2008) Effects of a saturated fat and high cholesterol diet on memory and hippocampal morphology in the middle-aged rat. J. Alzheimers Dis. 14, 133-145.
39. Hamel E., Nicolakakis N., Aboulkassim T., Ongali B. and Tong X. K. (2008) Oxidative stress and cerebrovascular dysfunction in mouse models of Alzheimer's disease. Exp. Physiol. 93, 116-120.
40. Hansson G. K. (2009) Inflammatory mechanisms in atherosclerosis. J. Thromb. Haemost. 7(Suppl. 1), 328-331.
41. Hardy J. and Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356.
42. Heilbronn L. K. and Campbell L. V. (2008) Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr. Pharm. Des. 14, 1225-1230.
43. Heneka M. T. and O'Banion M. K. (2007) Inflammatory processes in Alzheimer's disease. J. Neuroimmunol. 184, 69-91.
44. Hickman S. E. and El Khoury J. (2010) Mechanisms of mononuclear phagocyte recruitment in Alzheimer's disease. CNS Neurol. Disord. Drug Targets 9, 168-173.
45. Hickman S. E., Allison E. K. and El Khoury J. (2008) Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J. Neurosci. 28, 8354-8360.
46. Hong C. and Tontonoz P. (2008) Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr. Opin. Genet. Dev. 18, 461-467.
47. Hooijmans C. R., Van der Zee C. E., Dederen P. J., Brouwer K. M., Reijmer Y. D., van Groen T., Broersen L. M., Lutjohann D., Heerschap A. and Kiliaan A. J. (2009) DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice. Neurobiol. Dis. 33, 482-498.
48. Hooper C., Killick R. and Lovestone S. (2008) The GSK3 hypothesis of Alzheimer's disease. J. Neurochem. 104, 1433-1439. Hotamisligil G. S. (2006) Inflammation and metabolic disorders. Nature 444, 860-867.
49. Hotamisligil G. S. (2008) Inflammation and endoplasmic reticulum stress in obesity and diabetes. Int. J. Obes. (Lond) 32(Suppl. 7), S52-S54.
50. Huber J. D. (2008) Diabetes, cognitive function, and the blood-brain barrier. Curr. Pharm. Des. 14, 1594-1600.
51. Imbimbo B. P. (2009) An update on the efficacy of non-steroidal antiinflammatory drugs in Alzheimer's disease. Expert Opin. Investig. Drugs 18, 1147-1168.
52. Ishikawa M., Stokes K. Y., Zhang J. H., Nanda A. and Granger D. N. (2004) Cerebral microvascular responses to hypercholesterolemia: roles of NADPH oxidase and P-selectin. Circ. Res. 94, 239-244.
53. Jiang Q., Heneka M. and Landreth G. E. (2008) The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: Therapeutic implications. CNS Drugs 22, 1-14.
54. Jolivalt C. G., Lee C. A., Beiswenger K. K., Smith J. L., Orlov M., Torrance M. A. and Masliah E. (2008) Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: Parallels with Alzheimer's disease and correction by insulin. J. Neurosci. Res. 86, 3265-3274.
55. Julien C., Tremblay C., Phivilay A., Berthiaume L., Emond V., Julien P. and Calon F. (2010) High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model. Neurobiol. Aging 31, 1516-1531.
56. Kim B., Backus C., Oh S., Hayes J. M. and Feldman E. L. (2009a) Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology 150, 5294-5301.
57. Kim J., Basak J. M. and Holtzman D. M. (2009b) The role of apolipoprotein E in Alzheimer's disease. Neuron 63, 287-303.
58. Koch L., Wunderlich F. T., Seibler J., Konner A. C., Hampel B., Irlenbusch S., Brabant G., Kahn C. R., Schwenk F. and Bruning J. C. (2008) Central insulin action regulates peripheral glucose and fat metabolism in mice. J. Clin. Invest. 118, 2132-2147.
59. Kodl C. T. and Seaquist E. R. (2008) Cognitive dysfunction and diabetes mellitus. Endocr. Rev. 29, 494-511.
60. Kumar-Singh S. (2008) Cerebral amyloid angiopathy: Pathogenetic mechanisms and link to dense amyloid plaques. Genes Brain Behav 7(Suppl. 1), 67-82.
61. Levin-Allerhand J. A., Lominska C. E. and Smith J. D. (2002) Increased amyloid- levels in APPSWE transgenic mice treated chronically with a physiological high-fat high-cholesterol diet. J. Nutr. Health Aging 6, 315-319.
62. Li Z. G., Zhang W. and Sima A. A. (2007) Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 56, 1817-1824.
63. Liao J. K. and Laufs U. (2005) Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 45, 89-118.
64. Liao F. F. and Xu H. (2009) Insulin signaling in sporadic Alzheimer's disease. Sci. Signal. 2, pe36.
65. Libby P. (2006) Inflammation and cardiovascular disease mechanisms. Am. J. Clin. Nutr. 83, 456S-460S.
66. Lionetti L., Mollica M. P., Lombardi A., Cavaliere G., Gifuni G. and Barletta A. (2009) From chronic overnutrition to insulin resistance: The role of fat-storing capacity and inflammation. Nutr. Metab. Cardiovasc. Dis. 19, 146-152.
67. Luchsinger J. A. (2008) Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: An epidemiological perspective. Eur. J. Pharmacol. 585, 119-129.
68. Lucin K. M. andWyss-Coray T. (2009) Immune activation in brain aging and neurodegeneration: Too much or too little? Neuron 64, 110-122.
69. Ma Q. L., Yang F., Rosario E. R. et al. (2009) Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J. Neurosci. 29, 9078-9089.
70. Malm T., Koistinaho M., Muona A., Magga J. and Koistinaho J. (2010) The role and therapeutic potential of monocytic cells in Alzheimer's disease. Glia 58, 889-900.
71. Martins I. J., Hone E., Foster J. K., Sunram-Lea S. I., Gnjec A., Fuller S. J., Nolan D., Gandy S. E. and Martins R. N. (2006) Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol. Psychiatry 11, 721-736.
72. McAllister A. K. and van de Water J. (2009) Breaking boundaries in neural-immune interactions. Neuron 64, 9-12.
73. Merched A., Xia Y., Visvikis S., Serot J. M. and Siest G. (2000) Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol. Aging 21, 27-30.
74. Milanski M., Degasperi G., Coope A. et al. (2009) Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: Implications for the pathogenesis of obesity. J. Neurosci. 29, 359-370.
75. Milionis H. J., Florentin M. and Giannopoulos S. (2008) Metabolic syndrome and Alzheimer's disease: A link to a vascular hypothesis? CNS Spectr. 13, 606-613.
76. Moloney A. M., Griffin R. J., Timmons S., O'Connor R., Ravid R. and O'Neill C. (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF- 1 and insulin signalling. Neurobiol. Aging 31, 224-243.
77. de la Monte S. M. (2009) Insulin resistance and Alzheimer's disease. BMB Rep. 42, 475-481.
78. Moore A. H., Wu M., Shaftel S. S., Graham K. A. and O'Banion M. K. (2009) Sustained expression of interleukin-1beta in mouse hippocampus impairs spatial memory. Neuroscience 164, 1484-1495.
79. Morrison J. H. and Hof P. R. (1997) Life and death of neurons in the aging brain. Science 278, 412-419.
80. Mulder M., Jansen P. J., Janssen B. J., van de Berg W. D., van der Boom H., Havekes L. M., de Kloet R. E., Ramaekers F. C. and Blokland A. (2004) Low-density lipoprotein receptor-knockout mice display impaired spatial memory associated with a decreased synaptic density in the hippocampus. Neurobiol. Dis. 16, 212-219.
81. Neumann K. F., Rojo L., Navarrete L. P., Farias G., Reyes P. and Maccioni R. B. (2008) Insulin resistance and Alzheimer's disease: molecular links & clinical implications. Curr. Alzheimer Res. 5, 438-447.
82. Njie E. G., Boelen E., Stassen F. R., Steinbusch H. W., Borchelt D. R. and Streit W. J. (2010) Ex vivo cultures of microglia from young and aged rodent brain reveal age-related changes in microglial function. Neurobiol. Aging (in press).
83. Pasinetti G. M. and Eberstein J. A. (2008) Metabolic syndrome and the role of dietary lifestyles in Alzheimer's disease. J. Neurochem. 106, 1503-1514.
84. Prieur X., Roszer T. and Ricote M. (2009) Lipotoxicity in macrophages: Evidence from diseases associated with the metabolic syndrome. Biochim. Biophys. Acta 1801, 327-337.
85. Puglielli L., Tanzi R. E. and Kovacs D. M. (2003) Alzheimer's disease: The cholesterol connection. Nat. Neurosci. 6, 345-351.
86. Rahman A., Akterin S., Flores-Morales A., Crisby M., Kivipelto M., Schultzberg M. and Cedazo-Minguez A. (2005) High cholesterol diet induces tau hyperphosphorylation in apolipoprotein E deficient mice. FEBS Lett. 579, 6411-6416.
87. Refolo L. M., Malester B., LaFrancois J., Bryant-Thomas T., Wang R., Tint G. S., Sambamurti K., Duff K. and Pappolla M. A. (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7, 321-331.
88. Riddell D. R., Zhou H., Comery T. A. et al. (2007) The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol. Cell. Neurosci. 34, 621-628.
89. Rocchi A., Orsucci D., Tognoni G., Ceravolo R. and Siciliano G. (2009) The role of vascular factors in late-onset sporadic Alzheimer's disease. Genetic and molecular aspects. Curr. Alzheimer Res. 6, 224-237.
90. Rocha V. Z. and Libby P. (2009) Obesity, inflammation, and atherosclerosis. Nat. Rev. Cardiol. 6, 399-409.
91. Roriz-Filho J. S., Sa-Roriz T. M., Rosset I., Camozzato A. L., Santos A. C., Chaves M. L., Moriguti J. C. and Roriz-Cruz M. (2009) (Pre)diabetes, brain aging, and cognition. Biochim. Biophys. Acta 1792, 432-443.
92. Roses A. D. (1996) Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu. Rev. Med. 47, 387-400.
93. Salkovic-Petrisic M., Osmanovic J., Grunblatt E., Riederer P. and Hoyer S. (2009) Modeling sporadic Alzheimer's disease: The insulin resistant brain state generates multiple long-term morphobiological abnormalities inclusive hyperphosphorylated tau protein and amyloid-beta. A synthesis. J. Alzheimers Dis. 18, 729-750.
94. Sambamurti K., Granholm A. C., Kindy M. S., Bhat N. R., Greig N. H., Lahiri D. K. and Mintzer J. E. (2004) Cholesterol and Alzheimer's disease: Clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors. Curr. Drug Targets 5, 517-528.
95. Selkoe D. J. (1999) Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399, A23-A31.
96. Shineman D. W., Dain A. S., Kim M. L. and Lee V. M. (2009) Constitutively active Akt inhibits trafficking of amyloid precursor protein and amyloid precursor protein metabolites through feedback inhibition of phosphoinositide 3-kinase. Biochemistry 48, 3787-3794.
97. Small S. A. and Duff K. (2008) Linking Abeta and tau in late-onset Alzheimer's disease: A dual pathway hypothesis. Neuron 60, 534- 542.
98. Smith E. E. and Greenberg S. M. (2009) Beta-amyloid, blood vessels, and brain function. Stroke 40, 2601-2606.
99. Sparks D. L., Kuo Y. M., Roher A., Martin T. and Lukas R. J. (2000) Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations. Ann. N Y Acad. Sci. 903, 335-344.
100. Stokes K. Y. (2006) Microvascular responses to hypercholesterolemia: The interactions between innate and adaptive immune responses. Antioxid. Redox Signal. 8, 1141-1151.
101. Stranahan A. M., Norman E. D., Lee K., Cutler R. G., Telljohann R. S., Egan J. M. and Mattson M. P. (2008) Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus 18, 1085-1088.
102. Sun M. K. and Alkon D. L. (2006) Links between Alzheimer's disease and diabetes. Drugs Today (Barc) 42, 481-489.
103. Sun X. J. and Liu F. (2009) Phosphorylation of IRS proteins Yin-Yang regulation of insulin signaling. Vitam. Horm. 80, 351-387.
104. Takechi R., Galloway S., Pallebage-Gamarallage M. M., Lam V. and Mamo J. C. (2009) Dietary fats, cerebrovasculature integrity and Alzheimer's disease risk. Prog. Lipid Res. 49, 159-170.
105. Takeda S., Sato N., Uchio-Yamada K., Sawada K., Kunieda T., Takeuchi D., Kurinami H., Shinohara M., Rakugi H. and Morishita R. (2010) Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc. Natl Acad. Sci. USA 107, 7036-7041.
106. Takeuchi M. and Yamagishi S. (2008) Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr. Pharm. Des. 14, 973-978.
107. Thal D. R., Griffin W. S., de Vos R. A. and Ghebremedhin E. (2008) Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. Acta Neuropathol. 115, 599-609.
108. Thirumangalakudi L., Prakasam A., Zhang R., Bimonte-Nelson H., Sambamurti K., Kindy M. S. and Bhat N. R. (2008) High cholesterol- induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. J. Neurochem. 106, 475-485.
109. Tobinick E. (2009) Tumour necrosis factor modulation for treatment of Alzheimer's disease: rationale and current evidence. CNS Drugs 23, 713-725.
110. de la Torre J. C. (2009) Cerebrovascular and cardiovascular pathology in Alzheimer's disease. Int. Rev. Neurobiol. 84, 35-48.
111. Town T., Laouar Y., Pittenger C., Mori T., Szekely C. A., Tan J., Duman R. S. and Flavell R. A. (2008) Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat. Med. 14, 681-687.
112. Whitmer R. A. (2007) Type 2 diabetes and risk of cognitive impairment and dementia. Curr. Neurol. Neurosci. Rep. 7, 373-380.
113. Winocur G. and Greenwood C. E. (2005) Studies of the effects of high fat diets on cognitive function in a rat model. Neurobiol. Aging 26(Suppl. 1), 46-49.
114. Wollmer M. A. (2010) Cholesterol-related genes in Alzheimer's disease. Biochim. Biophys. Acta 1801, 762-773.
115. Wolozin B., Kellman W., Ruosseau P., Celesia G. G. and Siegel G. (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3- methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 1439-1443.
116. Wolozin B., Manger J., Bryant R., Cordy J., Green R. C. and McKee A. (2006) Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neurol. Scand. Suppl. 185, 63-70.
117. Wu A., Ying Z. and Gomez-Pinilla F. (2004) The interplay between oxidative stress and brain-derived neurotrophic factor modulates the outcome of a saturated fat diet on synaptic plasticity and cognition. Eur. J. Neurosci. 19, 1699-1707.
118. Xu F., Grande A. M., Robinson J. K., Previti M. L., Vasek M., Davis J. and Van Nostrand W. E. (2007) Early-onset subicular microvascular amyloid and neuroinflammation correlate with behavioral deficits in vasculotropic mutant amyloid beta-protein precursor transgenic mice. Neuroscience 146, 98-107.
119. Yan S. F., D'Agati V., Schmidt A. M. and Ramasamy R. (2007) Receptor for advanced glycation endproducts (RAGE): A formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging. Curr. Mol. Med. 7, 699-710.
120. Yan S. D., Bierhaus A., Nawroth P. P. and Stern D. M. (2009) RAGE and Alzheimer's disease: A progression factor for amyloid-beta-induced cellular perturbation? J. Alzheimer's Dis. 16, 833-843.
121. Yong V. W. and Rivest S. (2009) Taking advantage of the systemic immune system to cure brain diseases. Neuron 64, 55-60.
122. Zelcer N., Khanlou N., Clare R., Jiang Q., Reed-Geaghan E. G., Landreth G. E., Vinters H. V. and Tontonoz P. (2007) Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc. Natl Acad. Sci. USA 104, 10601- 10606.
123. Zeyda M. and Stulnig T. M. (2009) Obesity, inflammation, and insulin resistance - a mini-review. Gerontology 55, 379-386.
124. Zhao W. Q. and Townsend M. (2009) Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim. Biophys. Acta 1792, 482-496.
125. Zhu X., Smith M. A., Honda K., Aliev G., Moreira P. I., Nunomura A., Casadesus G., Harris P. L., Siedlak S. L. and Perry G. (2007) Vascular oxidative stress in Alzheimer disease. J. Neurol. Sci. 257, 240-246. (Pubitemid 46856513)
126. Zlokovic B. V. (2005) Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 28, 202-208.